Celldex Therapeutics, Inc. (CLDX)
USD 15.9
(-7.29%)
USD 15.9
(-7.29%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 465.62 Million USD | 32.0% |
| 2022 | 352.73 Million USD | -20.67% |
| 2021 | 444.65 Million USD | 88.54% |
| 2020 | 235.83 Million USD | 91.84% |
| 2019 | 122.93 Million USD | -21.1% |
| 2018 | 155.8 Million USD | -50.63% |
| 2017 | 315.62 Million USD | -17.67% |
| 2016 | 383.35 Million USD | 13.56% |
| 2015 | 337.58 Million USD | 36.11% |
| 2014 | 248.01 Million USD | -28.55% |
| 2013 | 347.09 Million USD | 176.48% |
| 2012 | 125.54 Million USD | 28.11% |
| 2011 | 97.99 Million USD | -10.87% |
| 2010 | 109.94 Million USD | -21.67% |
| 2009 | 140.36 Million USD | 101.11% |
| 2008 | 69.79 Million USD | 85.38% |
| 2007 | 37.64 Million USD | -38.76% |
| 2006 | 61.47 Million USD | 68.66% |
| 2005 | 36.45 Million USD | -20.42% |
| 2004 | 45.8 Million USD | 46.31% |
| 2003 | 31.3 Million USD | -11.15% |
| 2002 | 35.23 Million USD | -34.12% |
| 2001 | 53.48 Million USD | -15.86% |
| 2000 | 63.56 Million USD | 219.69% |
| 1999 | 19.88 Million USD | -12.41% |
| 1998 | 22.7 Million USD | 131.63% |
| 1997 | 9.8 Million USD | -43.02% |
| 1996 | 17.2 Million USD | -7.03% |
| 1995 | 18.5 Million USD | -10.63% |
| 1994 | 20.7 Million USD | -37.46% |
| 1993 | 33.1 Million USD | 47.77% |
| 1992 | 22.4 Million USD | 69.7% |
| 1991 | 13.2 Million USD | -15.38% |
| 1990 | 15.6 Million USD | 18.18% |
| 1989 | 13.2 Million USD | 1.54% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 845.58 Million USD | -2.68% |
| 2024 Q1 | 868.84 Million USD | 86.6% |
| 2023 Q3 | 280.25 Million USD | -6.37% |
| 2023 Q2 | 299.31 Million USD | -7.77% |
| 2023 FY | 465.62 Million USD | 32.0% |
| 2023 Q1 | 324.51 Million USD | -8.0% |
| 2023 Q4 | 465.62 Million USD | 66.14% |
| 2022 Q4 | 352.73 Million USD | -4.47% |
| 2022 FY | 352.73 Million USD | -20.67% |
| 2022 Q2 | 402.96 Million USD | -4.97% |
| 2022 Q1 | 424.04 Million USD | -4.64% |
| 2022 Q3 | 369.22 Million USD | -8.37% |
| 2021 FY | 444.65 Million USD | 88.54% |
| 2021 Q1 | 219.06 Million USD | -7.11% |
| 2021 Q2 | 204.55 Million USD | -6.63% |
| 2021 Q3 | 460.2 Million USD | 124.98% |
| 2021 Q4 | 444.65 Million USD | -3.38% |
| 2020 Q4 | 235.83 Million USD | -7.79% |
| 2020 Q3 | 255.77 Million USD | -2.15% |
| 2020 FY | 235.83 Million USD | 91.84% |
| 2020 Q1 | 112.5 Million USD | -8.48% |
| 2020 Q2 | 261.4 Million USD | 132.35% |
| 2019 FY | 122.93 Million USD | -21.1% |
| 2019 Q2 | 142.24 Million USD | -3.61% |
| 2019 Q1 | 147.57 Million USD | -5.28% |
| 2019 Q3 | 131.84 Million USD | -7.31% |
| 2019 Q4 | 122.93 Million USD | -6.76% |
| 2018 Q1 | 191.37 Million USD | -39.37% |
| 2018 Q3 | 168.28 Million USD | -5.66% |
| 2018 Q4 | 155.8 Million USD | -7.41% |
| 2018 FY | 155.8 Million USD | -50.63% |
| 2018 Q2 | 178.37 Million USD | -6.79% |
| 2017 Q4 | 315.62 Million USD | -1.19% |
| 2017 FY | 315.62 Million USD | -17.67% |
| 2017 Q2 | 346.07 Million USD | -3.88% |
| 2017 Q1 | 360.04 Million USD | -6.08% |
| 2017 Q3 | 319.41 Million USD | -7.7% |
| 2016 Q4 | 383.35 Million USD | 52.16% |
| 2016 Q2 | 271.2 Million USD | -10.18% |
| 2016 Q1 | 301.93 Million USD | -10.56% |
| 2016 FY | 383.35 Million USD | 13.56% |
| 2016 Q3 | 251.94 Million USD | -7.1% |
| 2015 Q1 | 407.7 Million USD | 64.39% |
| 2015 FY | 337.58 Million USD | 36.11% |
| 2015 Q2 | 383.21 Million USD | -6.01% |
| 2015 Q3 | 352.63 Million USD | -7.98% |
| 2015 Q4 | 337.58 Million USD | -4.27% |
| 2014 Q2 | 297.59 Million USD | -6.62% |
| 2014 Q1 | 318.69 Million USD | -8.18% |
| 2014 Q4 | 248.01 Million USD | -8.71% |
| 2014 FY | 248.01 Million USD | -28.55% |
| 2014 Q3 | 271.66 Million USD | -8.71% |
| 2013 Q3 | 180.95 Million USD | -7.79% |
| 2013 Q2 | 196.23 Million USD | -12.54% |
| 2013 Q1 | 224.36 Million USD | 78.72% |
| 2013 Q4 | 347.09 Million USD | 91.81% |
| 2013 FY | 347.09 Million USD | 176.48% |
| 2012 FY | 125.54 Million USD | 28.11% |
| 2012 Q4 | 125.54 Million USD | 4.76% |
| 2012 Q3 | 119.83 Million USD | -1.88% |
| 2012 Q1 | 136.74 Million USD | 39.54% |
| 2012 Q2 | 122.12 Million USD | -10.69% |
| 2011 Q4 | 97.99 Million USD | -9.64% |
| 2011 Q1 | 92.4 Million USD | -15.95% |
| 2011 Q2 | 118.47 Million USD | 28.22% |
| 2011 Q3 | 108.44 Million USD | -8.46% |
| 2011 FY | 97.99 Million USD | -10.87% |
| 2010 Q2 | 121.57 Million USD | -8.21% |
| 2010 Q4 | 109.94 Million USD | -1.67% |
| 2010 Q3 | 111.8 Million USD | -8.03% |
| 2010 Q1 | 132.44 Million USD | -5.64% |
| 2010 FY | 109.94 Million USD | -21.67% |
| 2009 Q2 | 54.41 Million USD | -14.29% |
| 2009 Q1 | 63.48 Million USD | -9.04% |
| 2009 Q3 | 48.1 Million USD | -11.6% |
| 2009 FY | 140.36 Million USD | 101.11% |
| 2009 Q4 | 140.36 Million USD | 191.8% |
| 2008 Q3 | 79.18 Million USD | -8.29% |
| 2008 Q1 | 40.8 Million USD | 8.38% |
| 2008 Q2 | 86.34 Million USD | 111.6% |
| 2008 FY | 69.79 Million USD | 85.38% |
| 2008 Q4 | 69.79 Million USD | -11.86% |
| 2007 Q1 | 54.34 Million USD | -11.61% |
| 2007 Q2 | 49.2 Million USD | -9.45% |
| 2007 Q3 | 43.4 Million USD | -11.8% |
| 2007 Q4 | 37.64 Million USD | -13.26% |
| 2007 FY | 37.64 Million USD | -38.76% |
| 2006 Q4 | 61.47 Million USD | -4.02% |
| 2006 Q3 | 64.05 Million USD | -6.56% |
| 2006 Q1 | 73.3 Million USD | 101.11% |
| 2006 Q2 | 68.54 Million USD | -6.49% |
| 2006 FY | 61.47 Million USD | 68.66% |
| 2005 Q1 | 40.17 Million USD | -12.29% |
| 2005 FY | 36.45 Million USD | -20.42% |
| 2005 Q4 | 36.45 Million USD | -9.02% |
| 2005 Q3 | 40.06 Million USD | -9.92% |
| 2005 Q2 | 44.47 Million USD | 10.71% |
| 2004 Q1 | 52.33 Million USD | 67.17% |
| 2004 FY | 45.8 Million USD | 46.31% |
| 2004 Q4 | 45.8 Million USD | -0.72% |
| 2004 Q3 | 46.13 Million USD | -5.66% |
| 2004 Q2 | 48.9 Million USD | -6.56% |
| 2003 Q3 | 35.17 Million USD | 22.2% |
| 2003 FY | 31.3 Million USD | -11.15% |
| 2003 Q4 | 31.3 Million USD | -10.99% |
| 2003 Q1 | 32.01 Million USD | -9.12% |
| 2003 Q2 | 28.78 Million USD | -10.11% |
| 2002 Q3 | 38.68 Million USD | -8.46% |
| 2002 FY | 35.23 Million USD | -34.12% |
| 2002 Q1 | 47.72 Million USD | -10.77% |
| 2002 Q2 | 42.26 Million USD | -11.44% |
| 2002 Q4 | 35.23 Million USD | -8.93% |
| 2001 Q3 | 46.57 Million USD | -12.68% |
| 2001 Q2 | 53.34 Million USD | -8.1% |
| 2001 Q1 | 58.04 Million USD | -8.68% |
| 2001 Q4 | 53.48 Million USD | 14.83% |
| 2001 FY | 53.48 Million USD | -15.86% |
| 2000 Q4 | 63.56 Million USD | 18.03% |
| 2000 Q3 | 53.85 Million USD | 150.28% |
| 2000 Q2 | 21.51 Million USD | -12.4% |
| 2000 Q1 | 24.56 Million USD | 23.54% |
| 2000 FY | 63.56 Million USD | 219.69% |
| 1999 FY | 19.88 Million USD | -12.41% |
| 1999 Q4 | 19.88 Million USD | -15.03% |
| 1999 Q3 | 23.4 Million USD | 41.82% |
| 1999 Q2 | 16.5 Million USD | -16.24% |
| 1999 Q1 | 19.7 Million USD | -13.22% |
| 1998 Q1 | 11.6 Million USD | 18.37% |
| 1998 Q4 | 22.7 Million USD | -9.56% |
| 1998 FY | 22.7 Million USD | 131.63% |
| 1998 Q3 | 25.1 Million USD | 156.12% |
| 1998 Q2 | 9.8 Million USD | -15.52% |
| 1997 Q1 | 15 Million USD | -12.79% |
| 1997 Q4 | 9.8 Million USD | -14.78% |
| 1997 Q2 | 13.4 Million USD | -10.67% |
| 1997 Q3 | 11.5 Million USD | -14.18% |
| 1997 FY | 9.8 Million USD | -43.02% |
| 1996 Q2 | 11.7 Million USD | -27.33% |
| 1996 FY | 17.2 Million USD | -7.03% |
| 1996 Q1 | 16.1 Million USD | -12.97% |
| 1996 Q4 | 17.2 Million USD | -10.88% |
| 1996 Q3 | 19.3 Million USD | 64.96% |
| 1995 Q2 | 14.9 Million USD | -17.22% |
| 1995 FY | 18.5 Million USD | -10.63% |
| 1995 Q4 | 18.5 Million USD | 58.12% |
| 1995 Q3 | 11.7 Million USD | -21.48% |
| 1995 Q1 | 18 Million USD | -13.04% |
| 1994 Q4 | 20.7 Million USD | -18.18% |
| 1994 Q3 | 25.3 Million USD | -8.99% |
| 1994 Q2 | 27.8 Million USD | -9.45% |
| 1994 FY | 20.7 Million USD | -37.46% |
| 1994 Q1 | 30.7 Million USD | -7.25% |
| 1993 Q3 | 17.2 Million USD | -10.42% |
| 1993 Q1 | 21 Million USD | 0.0% |
| 1993 FY | 33.1 Million USD | 47.77% |
| 1993 Q2 | 19.2 Million USD | -8.57% |
| 1993 Q4 | 33.1 Million USD | 92.44% |
| 1992 Q3 | 24.4 Million USD | -5.79% |
| 1992 Q1 | 27 Million USD | -3.57% |
| 1992 Q2 | 25.9 Million USD | -4.07% |
| 1992 FY | 22.4 Million USD | 69.7% |
| 1991 Q3 | 28.4 Million USD | -4.7% |
| 1991 Q4 | 28 Million USD | -1.41% |
| 1991 FY | 13.2 Million USD | -15.38% |
| 1991 Q1 | 13.2 Million USD | 3.94% |
| 1991 Q2 | 29.8 Million USD | 125.76% |
| 1990 Q3 | 13.5 Million USD | -11.18% |
| 1990 FY | 15.6 Million USD | 18.18% |
| 1990 Q4 | 12.7 Million USD | -5.93% |
| 1990 Q2 | 15.2 Million USD | -2.56% |
| 1990 Q1 | 15.6 Million USD | 32.2% |
| 1989 FY | 13.2 Million USD | 1.54% |
| 1989 Q4 | 11.8 Million USD | 0.0% |
| 1989 Q1 | 13.2 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 68.71% |
| Alkermes plc | 2.13 Billion USD | 78.203% |
| Agenus Inc. | 313.91 Million USD | -48.33% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 87.842% |
| Aptorum Group Limited | 20.64 Million USD | -2155.935% |
| Ardelyx, Inc. | 297.57 Million USD | -56.472% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 39.178% |
| Bicycle Therapeutics plc | 595.34 Million USD | 21.789% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -531.77% |
| ChromaDex Corporation | 54.96 Million USD | -747.149% |
| Chimerix, Inc. | 212.77 Million USD | -118.836% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1546.932% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -5.592% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 79.116% |
| Precision BioSciences, Inc. | 159.78 Million USD | -191.416% |
| Dyadic International, Inc. | 8.21 Million USD | -5565.089% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1367.004% |
| Fortress Biotech, Inc. | 167.52 Million USD | -177.943% |
| Lantern Pharma Inc. | 43.64 Million USD | -966.787% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -188.605% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -3109.749% |
| Incyte Corporation | 6.78 Billion USD | 93.134% |
| IO Biotech, Inc. | 150.71 Million USD | -208.939% |
| Jaguar Health, Inc. | 50.76 Million USD | -817.257% |
| Novavax, Inc. | 1.85 Billion USD | 74.903% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -22.402% |
| Opthea Limited | 188.79 Million USD | -146.636% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 44.107% |
| ContextLogic Inc. | 423 Million USD | -10.077% |
| MiMedx Group, Inc. | 239.04 Million USD | -94.785% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -168.024% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -8906.846% |
| NextCure, Inc. | 129.41 Million USD | -259.785% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -763.103% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1167.737% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1341.525% |
| Vaxcyte, Inc. | 1.4 Billion USD | 66.928% |
| PDS Biotechnology Corporation | 59.39 Million USD | -684.015% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 27.308% |
| Pharming Group N.V. | 462.85 Million USD | -0.599% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1103.793% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 25.921% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2360.553% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2360.553% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -181.652% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -928.169% |
| Acelyrin, Inc. | 742.69 Million USD | 37.305% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -6969.39% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -7172.013% |
| Summit Therapeutics Inc. | 202.94 Million USD | -129.431% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -526.062% |
| Senti Biosciences, Inc. | 119.48 Million USD | -289.698% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -103.916% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -176.872% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -5535.084% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -9653.867% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 0.76% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -276.559% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -69.35% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 1.525% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -4507.887% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -117.069% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -41027.35% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -12.513% |
| Immix Biopharma, Inc. | 19.92 Million USD | -2236.88% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -25.837% |
| MEI Pharma, Inc. | 41.37 Million USD | -1025.382% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1336.854% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -36.628% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -297.208% |
| Fortress Biotech, Inc. | 167.52 Million USD | -177.943% |
| Precigen, Inc. | 151.04 Million USD | -208.274% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1268.767% |
| AlloVir, Inc. | 190.79 Million USD | -144.044% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -23.689% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 8.018% |
| ImmuCell Corporation | 43.8 Million USD | -962.879% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 28.29% |
| Onconetix, Inc. | 88.82 Million USD | -424.228% |
| PureTech Health plc | 693.97 Million USD | 32.904% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -376.662% |
| Elevation Oncology, Inc. | 89.09 Million USD | -422.642% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -7407.691% |
| Seer, Inc. | 436.26 Million USD | -6.729% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -470.642% |
| Innoviva, Inc. | 1.24 Billion USD | 62.555% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -251.621% |
| ESSA Pharma Inc. | 149.12 Million USD | -212.245% |
| GlycoMimetics, Inc. | 45.31 Million USD | -927.5% |
| GT Biopharma, Inc. | 14.1 Million USD | -3200.213% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -51.23% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -92.644% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 1.331% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -818.451% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -389.042% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -73623.218% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 17.783% |
| Aptose Biosciences Inc. | 12.92 Million USD | -3503.215% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -2005.549% |
| Soligenix, Inc. | 9.79 Million USD | -4652.593% |
| Century Therapeutics, Inc. | 360.69 Million USD | -29.093% |
| Kura Oncology, Inc. | 448.93 Million USD | -3.718% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -71.093% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -2592.264% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -319.819% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -126.968% |
| Autolus Therapeutics plc | 375.38 Million USD | -24.041% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -85.04% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -31.095% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -847.706% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 29.571% |
| GRI Bio, Inc. | 2.95 Million USD | -15651.928% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -4290.543% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -173.071% |
| IGM Biosciences, Inc. | 423.41 Million USD | -9.97% |
| INmune Bio, Inc. | 57 Million USD | -716.875% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -109.265% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -454.706% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1682.86% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -6664.693% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -518.971% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -216.198% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -181.339% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 26.044% |
| Verastem, Inc. | 149.71 Million USD | -211.003% |
| Abeona Therapeutics Inc. | 64 Million USD | -627.519% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 9.085% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -201.461% |
| Histogen Inc. | 19.07 Million USD | -2341.289% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -1955.733% |
| Surrozen, Inc. | 46.08 Million USD | -910.475% |
| Organovo Holdings, Inc. | 6.34 Million USD | -7233.864% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10706.871% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -223.292% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -3845.323% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -518.625% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -5365.587% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -28.283% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -2473.321% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -8.436% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -3592.018% |
| Apollomics, Inc. | 55.38 Million USD | -740.679% |
| Amarin Corporation plc | 831.68 Million USD | 44.014% |
| Mesoblast Limited | 669.15 Million USD | 30.415% |
| Turnstone Biologics Corp. | 112.81 Million USD | -312.735% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 19.128% |
| Synaptogenix, Inc. | 31.11 Million USD | -1396.535% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -3721.627% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 15.041% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7829.263% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -6239.236% |
| Exelixis, Inc. | 2.94 Billion USD | 84.175% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1929.495% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -27.73% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 40.965% |
| NLS Pharmaceutics AG | 1.84 Million USD | -25114.809% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -5735.924% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -3068.608% |
| Gritstone bio, Inc. | 177.76 Million USD | -161.928% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -388.181% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -2506.763% |
| Avid Bioservices, Inc. | 336.55 Million USD | -38.35% |
| Insmed Incorporated | 1.32 Billion USD | 64.986% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -4736.002% |
| MediWound Ltd. | 66.45 Million USD | -600.623% |
| OmniAb, Inc. | 401.98 Million USD | -15.832% |
| Alector, Inc. | 621.82 Million USD | 25.12% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -29.846% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -8557.996% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -721.328% |
| Zai Lab Limited | 1.03 Billion USD | 55.068% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 2.681% |
| Aura Biosciences, Inc. | 255.07 Million USD | -82.545% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 37.919% |
| Immunic, Inc. | 54.29 Million USD | -757.524% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -74.9% |
| Veracyte, Inc. | 1.13 Billion USD | 59.077% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -3838.388% |
| FibroGen, Inc. | 423.52 Million USD | -9.94% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -13154.398% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -9730.395% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -8475.907% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 95.913% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -5188.211% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 10.016% |
| TG Therapeutics, Inc. | 329.58 Million USD | -41.276% |
| Galecto, Inc. | 38.22 Million USD | -1118.058% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1523.752% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 89.314% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -97.799% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1774.354% |
| XBiotech Inc. | 227.24 Million USD | -104.903% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -388.181% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -226.527% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -62.854% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -264.144% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -21.892% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 68.771% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -27.624% |
| Vaxxinity, Inc. | 44.35 Million USD | -949.821% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 9.93% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -2402.116% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -52.64% |
| NexImmune, Inc. | 8.59 Million USD | -5318.08% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -4245.485% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -2618.61% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.592% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -2002.046% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -118602.153% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -168.638% |
| Ainos, Inc. | 31.84 Million USD | -1362.314% |
| Pluri Inc. | 39.52 Million USD | -1077.997% |
| Prothena Corporation plc | 696.38 Million USD | 33.136% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -64.756% |
| Celularity Inc. | 143.88 Million USD | -223.602% |
| Rallybio Corporation | 115.62 Million USD | -302.722% |
| Cue Biopharma, Inc. | 61.53 Million USD | -656.748% |
| MeiraGTx Holdings plc | 458.16 Million USD | -1.628% |
| Omeros Corporation | 378.26 Million USD | -23.094% |
| Humacyte, Inc. | 128.22 Million USD | -263.138% |
| Immunocore Holdings plc | 597 Million USD | 22.006% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1389.577% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -579.45% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 55.623% |
| CalciMedica, Inc. | 12.18 Million USD | -3721.313% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -83.571% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -172.443% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -49.702% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 17.632% |
| Pulmatrix, Inc. | 33.95 Million USD | -1271.185% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1615.269% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -230.565% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 64.209% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -257.655% |
| Cytokinetics, Incorporated | 824.31 Million USD | 43.514% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2104.36% |
| Nutriband Inc. | 7.51 Million USD | -6094.193% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -489.745% |
| Vor Biopharma Inc. | 209.82 Million USD | -121.909% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 93.553% |
| Evogene Ltd. | 51.1 Million USD | -811.19% |
| ProKidney Corp. | 420.55 Million USD | -10.718% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -749.173% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -4790.897% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 14.78% |
| CorMedix Inc. | 82.05 Million USD | -467.423% |
| BioLineRx Ltd. | 63.92 Million USD | -628.396% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -15.664% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1551.16% |
| Atai Life Sciences N.V. | 293.47 Million USD | -58.658% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -185.434% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -265.433% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 17.152% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -381.422% |
| MediciNova, Inc. | 66.26 Million USD | -602.621% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -429.434% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -10334.534% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4915.792% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 20.844% |
| Biomea Fusion, Inc. | 199.92 Million USD | -132.899% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 75.534% |
| Mereo BioPharma Group plc | 66.49 Million USD | -600.202% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 4.013% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 24.026% |
| Absci Corporation | 234.48 Million USD | -98.579% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6265.373% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -36.993% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -182.058% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 11.532% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -67.677% |
| Allakos Inc. | 243.61 Million USD | -91.136% |
| Imunon, Inc. | 21.91 Million USD | -2024.398% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -80.69% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 25.082% |
| BioAtla, Inc. | 119.65 Million USD | -289.132% |
| NLS Pharmaceutics AG | 1.84 Million USD | -25114.809% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -14360.466% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 27.567% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -385.357% |
| XOMA Corporation | 234.3 Million USD | -98.73% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -110.467% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -270.003% |
| aTyr Pharma, Inc. | 122.06 Million USD | -281.452% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -202.546% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 19.757% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 5.056% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -321.5% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -2971.913% |
| Akari Therapeutics, Plc | 4.35 Million USD | -10591.78% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2632.981% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 73.136% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -14998.22% |
| UroGen Pharma Ltd. | 178.31 Million USD | -161.132% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 1.085% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -83688.813% |
| Orgenesis Inc. | 14.55 Million USD | -3099.746% |
| Entera Bio Ltd. | 11.76 Million USD | -3857.731% |
| GH Research PLC | 226.3 Million USD | -105.757% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -751.331% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -333.399% |
| Xencor, Inc. | 952.69 Million USD | 51.125% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -5882.023% |
| Replimune Group, Inc. | 487.72 Million USD | 4.53% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -5669.073% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 28.193% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -14998.22% |
| Portage Biotech Inc. | 7.77 Million USD | -5885.692% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -10334.534% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -68.13% |
| OncoCyte Corporation | 74.89 Million USD | -521.731% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -22800.65% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -7946.582% |
| Purple Biotech Ltd. | 44.3 Million USD | -951.029% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1264.435% |
| scPharmaceuticals Inc. | 94.47 Million USD | -392.837% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -2480.372% |
| HilleVax, Inc. | 344.43 Million USD | -35.186% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -14560.8% |
| Tharimmune, Inc. | 10.94 Million USD | -4153.703% |
| Genprex, Inc. | 10.67 Million USD | -4263.647% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 6.16% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -383.758% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -19093.199% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -11078.336% |
| OKYO Pharma Limited | 1.54 Million USD | -30110.723% |
| Savara Inc. | 177.56 Million USD | -162.231% |
| Curis, Inc. | 77.28 Million USD | -502.504% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2087.869% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -628.125% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -5658.434% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -2303.732% |
| BeiGene, Ltd. | 5.8 Billion USD | 91.979% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -3726.337% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 77.706% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -30.081% |
| Erasca, Inc. | 395.29 Million USD | -17.792% |
| bluebird bio, Inc. | 619.16 Million USD | 24.797% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10670.004% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 93.194% |
| DBV Technologies S.A. | 182.98 Million USD | -154.46% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10670.004% |
| Moderna, Inc. | 18.42 Billion USD | 97.473% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -2456.003% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -3918.876% |
| Molecular Templates, Inc. | 35.38 Million USD | -1215.962% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -236.764% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 40.979% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -53.29% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -347.951% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -48.555% |
| MacroGenics, Inc. | 306.82 Million USD | -51.759% |
| RenovoRx, Inc. | 1.46 Million USD | -31661.733% |
| Adicet Bio, Inc. | 207.29 Million USD | -124.62% |
| Prime Medicine, Inc. | 193.85 Million USD | -140.198% |
| Aditxt, Inc. | 44.57 Million USD | -944.514% |
| Adagene Inc. | 115.72 Million USD | -302.343% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -10353.688% |
| Quantum-Si incorporated | 298.25 Million USD | -56.12% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 68.696% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -5939.948% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -32.551% |
| SciSparc Ltd. | 11.18 Million USD | -4064.076% |
| Vericel Corporation | 353.65 Million USD | -31.661% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3712.674% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -718.316% |
| Generation Bio Co. | 374.75 Million USD | -24.247% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -82.838% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -193.647% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -36.402% |
| Invivyd, Inc. | 229.18 Million USD | -103.17% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 44.83% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -3726.243% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -155.292% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -2179.803% |
| 2seventy bio, Inc. | 565.42 Million USD | 17.65% |
| ADMA Biologics, Inc. | 329.18 Million USD | -41.45% |
| Clene Inc. | 52.34 Million USD | -789.603% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -692.768% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -258.467% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4915.792% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 28.77% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -349.399% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -257.114% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -377.311% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -555.84% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -91.969% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 76.245% |
| Evaxion Biotech A/S | 12.88 Million USD | -3512.699% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -84.729% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 38.138% |
| Trevena, Inc. | 40.6 Million USD | -1046.723% |
| Surrozen, Inc. | 46.08 Million USD | -910.475% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -106.16% |
| Cingulate Inc. | 3.49 Million USD | -13236.26% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -2700.09% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -608.825% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -3884.954% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -73.407% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 37.83% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -269.862% |
| Clearmind Medicine Inc. | 4.32 Million USD | -10667.463% |
| Kronos Bio, Inc. | 213.27 Million USD | -118.318% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -191.41% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5339.18% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -26.361% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2099.499% |
| ImmunityBio, Inc. | 504.45 Million USD | 7.696% |
| Korro Bio, Inc. | 221.66 Million USD | -110.061% |
| Kineta, Inc. | 10.28 Million USD | -4429.005% |
| BioVie Inc. | 25.2 Million USD | -1747.115% |
| Codexis, Inc. | 136.56 Million USD | -240.966% |
| Celularity Inc. | 143.88 Million USD | -223.602% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 26.714% |
| Celcuity Inc. | 191.21 Million USD | -143.504% |
| Virax Biolabs Group Limited | 5.48 Million USD | -8390.694% |
| Cibus, Inc. | 544.41 Million USD | 14.471% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -269.856% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -2166.487% |
| IN8bio, Inc. | 33.7 Million USD | -1281.314% |
| Kodiak Sciences Inc. | 479.37 Million USD | 2.867% |
| Annexon, Inc. | 297.67 Million USD | -56.422% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -169.133% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -238.714% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2118.011% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 84.428% |
| Eyenovia, Inc. | 28.77 Million USD | -1517.919% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -101.983% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6345.556% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -664.25% |
| Arcellx, Inc. | 825.13 Million USD | 43.569% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -470.363% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -0.725% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1414.234% |
| Moolec Science SA | 24.05 Million USD | -1835.975% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -50.142% |
| Geron Corporation | 394.07 Million USD | -18.157% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -357.799% |
| Royalty Pharma plc | 16.38 Billion USD | 97.158% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 21.739% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -6556.745% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -3771.412% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -105.975% |
| Humacyte, Inc. | 128.22 Million USD | -263.138% |
| Structure Therapeutics Inc. | 482.01 Million USD | 3.4% |
| 89bio, Inc. | 596.26 Million USD | 21.91% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -84.661% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -25069.027% |
| Genelux Corporation | 27.89 Million USD | -1569.333% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -420.818% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -102.95% |
| Notable Labs, Ltd. | 19.54 Million USD | -2282.821% |
| Liquidia Corporation | 120.43 Million USD | -286.634% |
| Mustang Bio, Inc. | 17.74 Million USD | -2524.434% |
| Immunovant, Inc. | 666.71 Million USD | 30.161% |
| Quantum-Si incorporated | 298.25 Million USD | -56.12% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -222.454% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -759.725% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -165.245% |
| Acasti Pharma Inc. | 73.3 Million USD | -535.235% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -10128.433% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1682.86% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 51.738% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -8871.76% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -1943.927% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -802.325% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -157.692% |
| PepGen Inc. | 143.05 Million USD | -225.495% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1118.377% |
| United Therapeutics Corporation | 7.16 Billion USD | 93.503% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -2327.037% |
| Solid Biosciences Inc. | 164.93 Million USD | -182.303% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7829.263% |
| Immuneering Corporation | 102.58 Million USD | -353.896% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10706.871% |
| Silo Pharma, Inc. | 7.74 Million USD | -5911.083% |
| Belite Bio, Inc | 94.64 Million USD | -391.988% |
| XOMA Corporation | 234.3 Million USD | -98.73% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -99.679% |
| Bionomics Limited | 27.64 Million USD | -1584.059% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -16.0% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -333.593% |
| uniQure N.V. | 831.68 Million USD | 44.014% |
| Cassava Sciences, Inc. | 151.66 Million USD | -207.014% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -10353.688% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -70.008% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1094.528% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -11331.72% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1164.226% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6345.556% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -13154.398% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -3838.981% |
| Altimmune, Inc. | 210.64 Million USD | -121.053% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 40.142% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -333.593% |
| Compugen Ltd. | 121.33 Million USD | -283.756% |
| Peak Bio, Inc. | 2.59 Million USD | -17833.458% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -170.2% |
| Benitec Biopharma Inc. | 52.21 Million USD | -791.835% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -36.204% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1239.048% |
| Zura Bio Limited | 100.84 Million USD | -361.735% |
| PolyPid Ltd. | 15.37 Million USD | -2929.059% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -290.345% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1239.048% |
| Instil Bio, Inc. | 325.63 Million USD | -42.993% |
| argenx SE | 4.54 Billion USD | 89.749% |
| Immunome, Inc. | 148.54 Million USD | -213.469% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -196.814% |
| Verona Pharma plc | 308.12 Million USD | -51.117% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -435.456% |
| Shattuck Labs, Inc. | 159.56 Million USD | -191.812% |
| CervoMed Inc. | 9.97 Million USD | -4569.1% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -147.075% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -3988.751% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -159.54% |
| Moolec Science SA | 24.05 Million USD | -1835.975% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -7511.418% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -169.235% |
| AnaptysBio, Inc. | 452.38 Million USD | -2.926% |
| Design Therapeutics, Inc. | 289.64 Million USD | -60.759% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -539.378% |
| NeurAxis, Inc. | 509.49 Thousand USD | -91289.368% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -8494.075% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1045.792% |
| Achilles Therapeutics plc | 161.45 Million USD | -188.393% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -435.456% |
| 180 Life Sciences Corp. | 5.25 Million USD | -8753.106% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -561.141% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5339.18% |
| Nutriband Inc. | 7.51 Million USD | -6094.193% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -82.824% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -133.63% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -510.963% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -703.97% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 11.569% |
| Palisade Bio, Inc. | 14.05 Million USD | -3213.599% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -121.416% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 68.101% |
| Neurogene Inc. | 222.57 Million USD | -109.202% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 27.991% |
| AEON Biopharma, Inc. | 6.84 Million USD | -6702.44% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -2.779% |
| Sesen Bio, Inc. | 189.17 Million USD | -146.137% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -71.27% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -3295.795% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 40.331% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -74.396% |
| Athira Pharma, Inc. | 160.24 Million USD | -190.572% |
| Vaccinex, Inc. | 3.63 Million USD | -12723.657% |
| HCW Biologics Inc. | 28.51 Million USD | -1532.996% |
| XOMA Corporation | 234.3 Million USD | -98.73% |
| Nektar Therapeutics | 398.03 Million USD | -16.982% |
| Arvinas, Inc. | 1.3 Billion USD | 64.309% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2632.981% |
| Merus N.V. | 458.49 Million USD | -1.556% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -127.84% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -158.389% |
| Rezolute, Inc. | 132.73 Million USD | -250.789% |
| Clene Inc. | 52.34 Million USD | -789.603% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -3020.013% |
| BeyondSpring Inc. | 24.8 Million USD | -1776.923% |
| Synlogic, Inc. | 75.55 Million USD | -516.316% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -3825.367% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -4872.522% |
| Peak Bio, Inc. | 2.59 Million USD | -17833.458% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -166.327% |
| Krystal Biotech, Inc. | 818.35 Million USD | 43.102% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -93.658% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 35.845% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -12916.616% |
| MannKind Corporation | 475.19 Million USD | 2.014% |
| Ikena Oncology, Inc. | 192.09 Million USD | -142.398% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -3381.584% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -299.546% |
| Gossamer Bio, Inc. | 311.91 Million USD | -49.28% |
| CohBar, Inc. | 16.36 Million USD | -2745.145% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1224.196% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6265.373% |
| Legend Biotech Corporation | 1.84 Billion USD | 74.812% |
| Mural Oncology plc | 301.74 Million USD | -54.311% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1391.677% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -8097.074% |
| Disc Medicine, Inc. | 367.99 Million USD | -26.53% |
| Champions Oncology, Inc. | 26.13 Million USD | -1681.827% |
| REGENXBIO Inc. | 573.97 Million USD | 18.876% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -17093.958% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -201.599% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -3755.939% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -36.935% |
| Vaxart, Inc. | 91.83 Million USD | -407.053% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -677.29% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -213.919% |
| Cellectis S.A. | 334.27 Million USD | -39.297% |
| Longeveron Inc. | 12.17 Million USD | -3723.51% |
| Repare Therapeutics Inc. | 253.9 Million USD | -83.389% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 85.737% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -131.832% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 77.706% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -28553.969% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -67.666% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -185.489% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -235.602% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1724.414% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.952% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 59.648% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3712.674% |
| Veru Inc. | 50.59 Million USD | -820.286% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -922.165% |
| Cingulate Inc. | 3.49 Million USD | -13236.26% |
| Passage Bio, Inc. | 150.54 Million USD | -209.294% |
| Context Therapeutics Inc. | 16.06 Million USD | -2798.803% |
| Exicure, Inc. | 11.58 Million USD | -3920.959% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -23.821% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -188.061% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -2564.99% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -39.935% |
| Nuvalent, Inc. | 732.38 Million USD | 36.423% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -3015.796% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -419.94% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -3181.143% |
| OmniAb, Inc. | 401.98 Million USD | -15.832% |
| Anew Medical, Inc. | 19.45 Million USD | -2293.237% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1642.189% |
| Lipocine Inc. | 23 Million USD | -1924.371% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -233.05% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -52.382% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -454.706% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -283.106% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -5768.015% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 47.224% |
| Ocugen, Inc. | 64.54 Million USD | -621.377% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -273.874% |
| Q32 Bio Inc. | 306.11 Million USD | -52.107% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -10965.28% |
| Alumis Inc. Common Stock | 89.61 Million USD | -419.603% |
| Equillium, Inc. | 50.53 Million USD | -821.486% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -519.226% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1028.149% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -27276.087% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1681.213% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -622.563% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -12392.967% |
| Dominari Holdings Inc. | 57.55 Million USD | -708.97% |
| Edesa Biotech, Inc. | 8.89 Million USD | -5137.392% |
| vTv Therapeutics Inc. | 11.01 Million USD | -4126.057% |
| Bio-Techne Corporation | 2.81 Billion USD | 83.448% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 50.313% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 42.618% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -67.694% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1016.558% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 30.252% |
| Nkarta, Inc. | 378.88 Million USD | -22.894% |
| BioCardia, Inc. | 2.98 Million USD | -15488.45% |
| Iterum Therapeutics plc | 26.25 Million USD | -1673.209% |